P. A. van der Lubbe

发表

Effects of psychosocial factors on monitoring treatment effect in newly diagnosed rheumatoid arthritis patients over time: response data from the tREACH study

D. van Zeben, J. Hazes, H. Xiong, 2018, Scandinavian journal of rheumatology.

A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis.

B. Dijkmans, F. Breedveld, U. Nässander, 1995, Arthritis and rheumatism.

Chimeric CD4 monoclonal antibody cM-T412 as a therapeutic approach to rheumatoid arthritis.

F. Breedveld, G. Riethmüller, F. Breedveld, 1993, Arthritis and rheumatism.

Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis.

F. Breedveld, P. Tak, M. Daha, 1995, Arthritis and rheumatism.

99mTc human immunoglobulin scintigraphy--a reliable method to detect joint activity in rheumatoid arthritis.

M. Westedt, F. Breedveld, E. van der Velde, 1992, The Journal of rheumatology.

Treatment with a chimeric CD4 monoclonal antibody is associated with a relative loss of CD4+/CD45RA+ cells in patients with rheumatoid arthritis.

F. Breedveld, P. Tak, J. Woody, 1997, Journal of autoimmunity.

Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial

D. van Zeben, A. Gerards, M. V. van Krugten, 2014, Annals of the rheumatic diseases.

Catastrophic manifestation of the antiphospholipid syndrome.

F. Breedveld, E. Boets, P. A. van der Lubbe, 1999, The Journal of rheumatology.

Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial

D. van Zeben, A. Gerards, J. Luime, 2012, Annals of the rheumatic diseases.

Association of low baseline levels of erythrocyte folate with treatment nonresponse at three months in rheumatoid arthritis patients receiving methotrexate.

D. van Zeben, S. Pluijm, J. Lindemans, 2013, Arthritis and rheumatism.